CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.58B, above the global median of $1.18B
- PositionCurrent ratio is 0.88×, lower than 95% of its Biotechnology peers (median 5.28×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
17.31BCNY2.58B · vs all stocks (USD)
Revenue (TTM)
1.25BCNY186.22M · vs all stocks (USD)
Profit Margin
-71.88%vs Biotechnology peers
Beta
0.7270xvs all stocks
52-Week Change
-35.24%vs all stocks
Market Capitalization
17.31BCNY2.58B · vs all stocks (USD)
Enterprise Value
18.08BCNY2.70B · vs all stocks (USD)
Forward P/E
24.70xvs Biotechnology peers
Price to Sales (TTM)
13.88xvs Biotechnology peers
Enterprise to Revenue
14.49xvs Biotechnology peers
Enterprise to EBITDA
-28.68xvs Biotechnology peers
Gross Margin
91.02%vs Biotechnology peers
Profit Margin
-71.88%vs Biotechnology peers
Operating Margin
-48.99%vs Biotechnology peers
Return on Assets (TTM)
-12.66%vs Biotechnology peers
Revenue (TTM)
1.25BCNY186.22M · vs all stocks (USD)
Revenue per Share (TTM)
2.60CNYUpdated Sep 22, 2026Quarterly Revenue Growth
-25.70%vs Biotechnology peers
Gross Profit (TTM)
1.10BCNY164.09M · vs all stocks (USD)
EBITDA (TTM)
-630.34MCNY-94.09M · vs all stocks (USD)
Net Income (TTM)
-896.77MCNY-133.86M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-35.31%vs Biotechnology peers
Operating Cash Flow (TTM)
-281.51MCNY-42.02M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-232.64MCNY-34.73M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
-7.94MCNYFY2025 · Dec 31, 2025Revenue
1.56BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
107.68MCNYFY2025 · Dec 31, 2025Gross Profit
1.45BCNYFY2025 · Dec 31, 2025Operating Income
-337.49MCNY-50.38M · vs all stocks (USD)
Pre-tax Income
-563.62MCNYFY2025 · Dec 31, 2025Income Tax Expense
2.58MCNYFY2025 · Dec 31, 2025Net Income
-566.20MCNYFY2025 · Dec 31, 2025EBIT
-479.79MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-286.05MCNYFY2025 · Dec 31, 2025Research & Development
837.85MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
625.15MCNYFY2025 · Dec 31, 2025Other Operating Expenses
15.30MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.88MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
83.83MCNYFY2025 · Dec 31, 2025EPS (Basic)
-1.32CNYFY2025 · Dec 31, 2025EPS (Diluted)
-1.32CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
427.92MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
427.92MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-566.20MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
1.35MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-369.14MCNYFY2025 · Dec 31, 2025Free Cash Flow
-585.66MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
770.33MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-566.20MCNYFY2025 · Dec 31, 2025Other Non-cash Items
103.61MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
174.26MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-80.80MCNYFY2025 · Dec 31, 2025Capital Expenditures
-216.52MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.77BCNYFY2025 · Dec 31, 2025Sale of Investments
1.69BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-291.98MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
2.39BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.79BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-111.83MCNYFY2025 · Dec 31, 2025Other Financing Charges
537.82MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
1.02BCNYFY2025 · Dec 31, 2025Shares Outstanding
470.34MSharesUpdated Sep 22, 2026Float Shares
123.56MSharesUpdated Sep 22, 2026% Held by Insiders
78.78%vs all stocks
% Held by Institutions
2.93%vs all stocks
Total Cash (MRQ)
1.03BCNY153.35M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.18CNYUpdated Sep 22, 2026Total Debt (MRQ)
2.78BCNY414.43M · vs all stocks (USD)
Current Ratio (MRQ)
0.8760xvs Biotechnology peers
Book Value per Share (MRQ)
-0.3150CNYUpdated Sep 22, 2026Total Assets
3.82BCNY570.85M · vs all stocks (USD)
Total Current Assets
1.90BCNYFY2025 · Dec 31, 2025Total Liabilities
3.70BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.93BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
968.86MCNYFY2025 · Dec 31, 2025Total Current Liabilities
2.74BCNYFY2025 · Dec 31, 2025Cash
770.33MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
770.33MCNYFY2025 · Dec 31, 2025Other Short-term Investments
88.29MCNYFY2025 · Dec 31, 2025Accounts Receivable
540.99MCNYFY2025 · Dec 31, 2025Inventory
336.36MCNYFY2025 · Dec 31, 2025Accounts Payable
130.25MCNYFY2025 · Dec 31, 2025Short-term Debt
2.29BCNYFY2025 · Dec 31, 2025Long-term Debt
845.98MCNYFY2025 · Dec 31, 2025Common Stock (Book)
445.34MCNYFY2025 · Dec 31, 2025Retained Earnings
-4.41BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
120.33MCNY17.96M · vs all stocks (USD)
52-Week Low
31.35CNYUpdated Sep 22, 202652-Week High
58.29CNYUpdated Sep 22, 202652-Week Change
-35.24%vs all stocks
Beta
0.7270xvs all stocks
50-Day MA
35.77CNYUpdated Sep 22, 2026200-Day MA
39.47CNYUpdated Sep 22, 2026Avg 10-Day Volume
2.06MSharesUpdated Sep 22, 2026Avg 30-Day Volume
2.94MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
-2.05CNYUpdated Sep 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.88×, lower than 95% of its Biotechnology peers (median 5.28×)Significant
Current ratio: 0.88Industry median: 5.28Industry P5: 0.98Peers compared: 193
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.91Profit Margin: -0.72
Financial Health
Altman Z-Score 0.92: distress zoneCritical
Altman Z-Score: 0.92
High structural barrier to entryNotable
Barrier to Entry: 4.17
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.58B, above the global median of $1.18BNotable
Market cap (USD): 2,584,320,112.729Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
MBX Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Joincare Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Axogen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Heron Neutron Medical Corp.
Tier 1ProductionApproval-Gated PipelineRule
NewAmsterdam Pharma Co. N.V.
Tier 1ProductionApproval-Gated PipelineRule
MicroPort Scientific Corporation
Tier 1ProductionApproval-Gated PipelineRule
uniQure N.V.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Beam Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Disc Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule